AstraZeneca (AZN.L), opens new tab said on Friday its blockbuster cancer drug Imfinzi helped improve overall and progression-free survival in patients with limited-stage small...
The US Food and Drug Administration (FDA) has approved Bristol-Myers Squibb's lung cancer drug Augtyro that was acquired as part of the company's $4.1...
AstraZeneca said on Friday its and Daiichi Sankyo's cancer drug Enhertu was recommended by the European Medicines Agency's human medicines committee as a monotherapy...
The US Food and Drug Administration approved Mirati Therapeutics Inc’s (MRTX.O) lung cancer drug adagrasib, the company said on Monday, sending its shares up...
AstraZeneca’s Imfinzi (durvalumab) in combination with Imjudo (tremelimumab) plus platinum-based chemotherapy has been approved in the US for the treatment of adult patients with...
Cancer deaths in the United States fell 2.2% from 2016 to 2017 - the largest single-year drop ever recorded - fueled in large part by progress against lung cancer, the leading cause of cancer death, the American Cancer Society (ACS) reported Wednesday.
Tecentriq is approved by the FDA to treat adults with metastatic NSCLC who have disease progression during or following platinum-containing chemotherapy
Invasive follow-up tests to examine abnormalities found with lung cancer screening may lead to more complications and extra healthcare costs than doctors previously thought,...
BOSTON: Genetic changes in the cells lining the inside of the nose might someday help doctors diagnose lung cancer, a recent study suggests.
“The idea...
COPENHAGEN: Lung cancer patients on Roche's immune system-boosting drug Tecentriq lived on average 4.2 months longer than those taking chemotherapy in a pivotal study,...
CHICAGO: A new mobile application could help doctors better provide care to patients with advanced lung cancer, perhaps even extending life expectancy, according to a study presented in the United States Monday.